Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.

Name: Αlpha¹ Rigor Record — Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
Item: Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
Rating: 59
Author: Αlpha¹

Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, Yun H, Hayes P, Bromell R, Ayorinde M, Fernandez N, Varma R, Sigei F, Ward M, Pindolia H, Sewell S, Amini F, Blie J, Wilson B, Faley P, McCullough J, Tokpah F, Wisseh C, Towalid E, Hadawale S, Sayeed E, Hunt D, Keshavarzi N, Barin B, Maljkovic Berry I, Parks CL, Truter SG, Walker K, Vekemans J, Lehrman J, Engelbrecht M, Malherbe M, Laufer D, Philiponis V, Higgs E, Mutua G, Fast PE, Gupta SB, rVSVΔG-LASV-GPC Study Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 3 high issues for “Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce−0.5★
IntegrityIntegrity concern−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This Phase 1 trial is methodologically sound with clear randomization, blinding, and appropriate statistical reporting for an early-phase study. The main weaknesses are missing explicit ethics committee details, informed consent description, and a data availability statement, along with minor reporting gaps such as unspecified statistical software and randomization method.

Both reviewers agreed on study type (interventional) and on most dimensions; they diverged on ethical approvals (pass vs. warn), where the more conservative warn was adopted due to missing explicit IRB name and informed consent. The statistics verification component checked only 1 test (inconsistent), so statistical correctness beyond that is unverified.

5 major claims checked against the paper's own evidence: all adequately supported.

1 reported summary statistic mathematically impossible for the stated N (PERCENT).

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites prior work on Lassa fever outbreaks, the absence of approved vaccines, and the development of rVSVΔG-LASV-GPC, including its 100% efficacy in non-human primates. The rationale for the study is logically linked to the need for a vaccine and the promising preclinical data. The paper does not explicitly discuss limitations of prior research, but the premise is well-established.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on Lassa fever, the lack of approved vaccines, and the development of the rVSV vector platform, including the licensed ERVEBO vaccine.

Evidence

direct quote[Introduction, paragraph 1]

“No vaccines are approved for Lassa fever to alleviate health and economic burdens or to prepare for pandemics.”